Department of Ultrasound, Shunde Women and Children's Hospital (Maternity and Child Healthcare Hospital of Shunde Foshan), Guangdong Medical University, Foshan, China.
Dongguan Key Laboratory of Environmental Medicine, School of Public Health, Guangdong Medical University, Dongguan, China.
Int J Biol Markers. 2020 Dec;35(4):3-11. doi: 10.1177/1724600820965579. Epub 2020 Nov 18.
Recently, many studies have demonstrated that long non-coding RNAs (lncRNAs) are abnormally expressed in hepatocellular carcinoma (HCC) and may serve as a potential molecular biomarker to evaluate the prognosis of hepatocellular carcinoma. Therefore, we accomplished a meta-analysis built on current studies to assess the prognostic value of lncRNAs in hepatocellular carcinoma.
The PubMed database was carefully searched to collect all eligible studies until February 20, 2019. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) of the overall survival, relapse-free survival, and progression-free survival were calculated to evaluate the prognostic significance of lncRNAs expression in hepatocellular carcinoma using Stata12.0 software. Heterogeneity, sensitivity analysis, and publication bias were also evaluated.
The results showed that the expression level of lncRNAs was significantly correlated with clinical outcomes. Abnormally expressed lncRNAs predicted poor overall survival (HR=2.19, 95% CI: 1.99-2.42, <0.001; I=44.7%, =0.005), relapse-free survival (HR=2.68, 95% CI: 1.74-4.14, <0.001; I=0.0%, =0.763) and progression-free survival of hepatocellular carcinoma patients (HR=2.44, 95% CI: 1.53-3.89, <0.001; I=0.0%, =0.336). Statistical significance was also noted in subgroup meta-analyses that were stratified by follow-up time, cutoff value, and quality score. Moreover, the pooled results indicated that lncRNAs expression was significantly associated with tumor size (HR=1.48, 95% CI: 1.24-1.79), tumor number (HR=1.34, 95% CI: 1.08-1.66), and tumor node metastasis stage (HR=2.10, 95% CI: 1.48-2.99), but not liver cirrhosis and tumor differentiation (>0.05).
This meta-analysis indicates that lncRNAs are strongly associated with prognosis in hepatocellular carcinoma and may serve as a promising indicator for prognostic evaluation of patients with hepatocellular carcinoma. But larger clinical studies are needed to verify its feasibility.
最近，许多研究表明长链非编码 RNA（lncRNA）在肝细胞癌（HCC）中异常表达，可能作为评估肝细胞癌预后的潜在分子生物标志物。因此，我们进行了一项基于现有研究的荟萃分析，以评估 lncRNA 在肝细胞癌中的预后价值。
仔细搜索 PubMed 数据库以收集所有符合条件的研究，直到 2019 年 2 月 20 日。使用 Stata12.0 软件计算总生存期、无复发生存期和无进展生存期的合并风险比（HR）和 95%置信区间（CI），以评估 lncRNA 在肝细胞癌中的表达对预后的意义。还评估了异质性、敏感性分析和发表偏倚。
结果表明，lncRNA 的表达水平与临床结局显著相关。异常表达的 lncRNA 预测总生存期不良（HR=2.19，95%CI：1.99-2.42，<0.001；I=44.7%，=0.005）、无复发生存期（HR=2.68，95%CI：1.74-4.14，<0.001；I=0.0%，=0.763）和肝细胞癌患者无进展生存期（HR=2.44，95%CI：1.53-3.89，<0.001；I=0.0%，=0.336）。根据随访时间、截断值和质量评分进行亚组荟萃分析也具有统计学意义。此外，汇总结果表明，lncRNA 表达与肿瘤大小（HR=1.48，95%CI：1.24-1.79）、肿瘤数量（HR=1.34，95%CI：1.08-1.66）和肿瘤淋巴结转移分期（HR=2.10，95%CI：1.48-2.99）显著相关，但与肝硬化和肿瘤分化无关（>0.05）。
这项荟萃分析表明，lncRNA 与肝细胞癌的预后密切相关，可能成为评估肝细胞癌患者预后的有前途的指标。但需要更大的临床研究来验证其可行性。
Zotero 插件